Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (3y) (2018 - 2026)

Corvus Pharmaceuticals (CRVS) Profit After Tax Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Corvus Pharmaceuticals 1.17 Bn 934.14 Mn - -20.93%

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.93%
Sep 30, 2025 11.85%
Jun 30, 2025 1.48%
Mar 31, 2025 56.53%
Sep 30, 2024 -54.75%
Jun 30, 2024 28.69%
Mar 31, 2024 21.04%
Dec 31, 2023 -30.26%
Sep 30, 2023 15.08%
Jun 30, 2023 15.06%
Mar 31, 2023 15.25%
Dec 31, 2022 15.13%
Sep 30, 2022 -10.46%
Jun 30, 2022 13.63%
Mar 31, 2022 10.68%
Dec 31, 2021 -0.18%
Sep 30, 2021 -0.59%
Jun 30, 2021 -0.35%
Mar 31, 2021 6.79%
Dec 31, 2020 62.52%